The review is broad in nature with an emphasis on the most studied TFs (NF-κB, A 20, p53, HIF-1α, STAT, etc.), their relationship with diseases (cancer, inflammation, neurodegeneration, etc.), current and promising approaches to regulating their activity, mechanisms of drug action, as well as the difficulties of developing highly specific and safe therapeutic agents. Here, TP53 is linked to cancer.